[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE314093T1 - Pharmazeutische formulierung enthaltend iota- carrageenan und mindestens ein gel-bildende neutrale polymer - Google Patents

Pharmazeutische formulierung enthaltend iota- carrageenan und mindestens ein gel-bildende neutrale polymer

Info

Publication number
ATE314093T1
ATE314093T1 AT02744027T AT02744027T ATE314093T1 AT E314093 T1 ATE314093 T1 AT E314093T1 AT 02744027 T AT02744027 T AT 02744027T AT 02744027 T AT02744027 T AT 02744027T AT E314093 T1 ATE314093 T1 AT E314093T1
Authority
AT
Austria
Prior art keywords
gel
pharmaceutical formulation
formulation containing
iota carrageenan
neutral polymer
Prior art date
Application number
AT02744027T
Other languages
English (en)
Inventor
Khoo Cynthia Gaik-Lim
Helena Gustafsson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0102069A external-priority patent/SE0102069D0/xx
Priority claimed from SE0201660A external-priority patent/SE0201660D0/xx
Application filed filed Critical
Application granted granted Critical
Publication of ATE314093T1 publication Critical patent/ATE314093T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02744027T 2001-06-21 2002-06-19 Pharmazeutische formulierung enthaltend iota- carrageenan und mindestens ein gel-bildende neutrale polymer ATE314093T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE0102069A SE0102069D0 (sv) 2001-06-21 2001-06-21 Pharmaceutical formulation
SE0104049 2001-11-30
SE0201660A SE0201660D0 (sv) 2002-05-31 2002-05-31 Pharmaceutical formulation
PCT/SE2002/001217 WO2003000293A1 (en) 2001-06-21 2002-06-19 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
ATE314093T1 true ATE314093T1 (de) 2006-01-15

Family

ID=27354711

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02744027T ATE314093T1 (de) 2001-06-21 2002-06-19 Pharmazeutische formulierung enthaltend iota- carrageenan und mindestens ein gel-bildende neutrale polymer

Country Status (31)

Country Link
US (1) US7700582B2 (de)
EP (1) EP1401502B1 (de)
JP (1) JP2005501024A (de)
KR (1) KR20040011542A (de)
CN (1) CN1518462A (de)
AR (1) AR034517A1 (de)
AT (1) ATE314093T1 (de)
AU (1) AU2002345463B2 (de)
BG (1) BG108516A (de)
BR (1) BR0210489A (de)
CA (1) CA2450449A1 (de)
CO (1) CO5550466A2 (de)
CZ (1) CZ299859B6 (de)
DE (1) DE60208369T2 (de)
DK (1) DK1401502T3 (de)
EE (1) EE200400028A (de)
ES (1) ES2254699T3 (de)
HU (1) HUP0400850A3 (de)
IL (2) IL159217A0 (de)
IS (1) IS2347B (de)
MX (1) MXPA03011546A (de)
MY (1) MY130332A (de)
NO (1) NO20035627D0 (de)
NZ (1) NZ530086A (de)
PL (1) PL366432A1 (de)
RU (1) RU2323006C2 (de)
SI (1) SI1401502T1 (de)
SK (1) SK286238B6 (de)
UA (1) UA77959C2 (de)
WO (1) WO2003000293A1 (de)
ZA (1) ZA200309316B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
PL374280A1 (en) * 2001-11-13 2005-10-03 Yamanouchi Pharma Technologies, Inc. Soluble drug extended release system
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US7442387B2 (en) * 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
US20050042289A1 (en) * 2003-04-29 2005-02-24 Yamanouchi Pharma Technologies, Inc. Tablets and methods for modified release of hydrophylic and other active agents
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
SE0303220D0 (sv) * 2003-11-28 2003-11-28 Astrazeneca Ab New process
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
MX2007004741A (es) 2004-10-21 2007-09-07 Eurand Pharmaceuticals Ltd Composiciones farmaceuticas con sabor enmascarado con formadores de poro gastrosolubles.
CA2584469A1 (en) * 2004-10-26 2006-05-04 Mcneil-Ppc, Inc. Burst-release polymer composition and dosage forms comprising the same
US9161918B2 (en) * 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
TW200827336A (en) 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
NZ579008A (en) * 2007-02-01 2012-02-24 Takeda Pharmaceutical Solid preparation comprising alogliptin and pioglitazone
TW200900033A (en) * 2007-06-21 2009-01-01 Wen-Qing Li Automatic brewing machine
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030
ES2402342T3 (es) 2008-08-01 2013-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Composición de quetiapina
TWI478733B (zh) * 2009-05-13 2015-04-01 Wyeth Llc 突釋藥物釋放組合物
TWI471146B (zh) 2009-12-02 2015-02-01 Aptalis Pharma Ltd 菲索特芬那定（ｆｅｘｏｆｅｎａｄｉｎｅ）微膠囊及包含其之組合物

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU178398B (en) 1979-06-12 1982-04-28 Gyogyszerkutato Intezet Process for producing new agmatine derivatives of activity against haemagglutination
JPS57149217A (en) 1981-03-11 1982-09-14 Kaken Pharmaceut Co Ltd Slow-releasing pharmaceutical preparation
HU192646B (en) 1984-12-21 1987-06-29 Gyogyszerkutato Intezet Process for preparing new n-alkyl-peptide aldehydes
IL77748A (en) 1985-02-04 1991-11-21 Merrell Dow Pharma Amino acid and peptide derivatives as peptidase inhibitors
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
EP0362002B1 (de) 1988-09-01 1995-07-26 Merrell Dow Pharmaceuticals Inc. HIV Protease-Hemmer
ZA897514B (en) 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
IT1229491B (it) * 1988-12-28 1991-09-03 Roussel Maestretti S P A Ora R Derivati della 1,2,5,6-tetraidropiridina, loro procedimento di preparazione e loro impiego come sostanze medicinali
TW201303B (de) 1990-07-05 1993-03-01 Hoffmann La Roche
CA2075154A1 (en) 1991-08-06 1993-02-07 Neelakantan Balasubramanian Peptide aldehydes as antithrombotic agents
SE9102462D0 (sv) 1991-08-28 1991-08-28 Astra Ab New isosteric peptides
US5169638A (en) 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
ZA928581B (en) 1991-11-12 1994-05-06 Lilly Co Eli Antithrombotic agents
SE9103612D0 (sv) 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
CA2131367A1 (en) 1992-03-04 1993-09-16 Sandor Bajusz New anticoagulant peptide derivatives and pharmaceutical compositions containing the same as well as a process for the preparation thereof
TW223629B (de) 1992-03-06 1994-05-11 Hoffmann La Roche
US5780631A (en) 1993-06-03 1998-07-14 Astra Aktiebolag Starting materials in the synthesis of thrombin and kininogenase inhibitors
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
SE9301912D0 (sv) 1993-06-03 1993-06-03 Ab Astra Process for the production of aminoalkylguandines
US6984627B1 (en) 1993-06-03 2006-01-10 Astrazeneca Ab Peptide derivatives
EP0648780A1 (de) 1993-08-26 1995-04-19 Bristol-Myers Squibb Company Heterozyklische Thrombinhemmer
TW394760B (en) 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
AU1025795A (en) 1994-01-27 1995-08-03 Mitsubishi Chemical Corporation Prolineamide derivatives
US5707966A (en) 1994-03-04 1998-01-13 Eli Lilly And Company Antithrombotic agents
ZA951617B (en) 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.
US5705487A (en) 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
US5561146A (en) 1994-06-10 1996-10-01 Bristol-Myers Squibb Company Modified guanidino and amidino thrombin inhibitors
DE4421052A1 (de) 1994-06-17 1995-12-21 Basf Ag Neue Thrombininhibitoren, ihre Herstellung und Verwendung
US5498724A (en) 1994-06-28 1996-03-12 Aktiebolaget Astra Pyrazoleamidine compounds
MX9706069A (es) 1995-02-17 1997-10-31 Basf Ag Nuevos inhibidores de la trombina.
US5710130A (en) 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
US6083532A (en) 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
US5695781A (en) * 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
SA96170106A (ar) 1995-07-06 2005-12-03 أسترا أكتيبولاج مشتقات حامض أميني جديدة
TW541316B (en) 1995-12-21 2003-07-11 Astrazeneca Ab Prodrugs of thrombin inhibitors
SE9602263D0 (sv) 1996-06-07 1996-06-07 Astra Ab New amino acid derivatives
CA2258915A1 (en) 1996-06-25 1997-12-31 Michael Robert Wiley Anticoagulant agents
SE9602646D0 (sv) 1996-07-04 1996-07-04 Astra Ab Pharmaceutically-useful compounds
DE19632772A1 (de) 1996-08-14 1998-02-19 Basf Ag Neue Benzamidine
AR013084A1 (es) 1997-06-19 2000-12-13 Astrazeneca Ab Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados
IT1297461B1 (it) * 1997-10-29 1999-12-17 Ciocca Maurizio Preparazione di compresse a rilascio controllato a base di complessi tra carragenano e farmaci basici solubili
SE9704543D0 (sv) 1997-12-05 1997-12-05 Astra Ab New compounds
US6251430B1 (en) * 1998-02-04 2001-06-26 Guohua Zhang Water insoluble polymer based sustained release formulation
US6174913B1 (en) 1998-06-05 2001-01-16 The University Of North Carolina At Chapel Hill Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents
SE9802938D0 (sv) 1998-09-01 1998-09-01 Astra Ab Improved stability for injection solutions
SE9802973D0 (sv) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
SE9802974D0 (sv) 1998-09-03 1998-09-03 Astra Ab New crystalline forms
CA2341410C (en) * 1998-09-04 2007-11-20 Scios Inc. Hydrogel compositions for the controlled release administration of growth factors
SE9804313D0 (sv) 1998-12-14 1998-12-14 Astra Ab New compounds
EP1150996B1 (de) 1999-01-13 2007-11-21 AstraZeneca AB Neue amidinbenzylamin-derivate und ihre verwendung als thrombin-inhibitoren
SE9902550D0 (sv) 1999-07-02 1999-07-02 Astra Ab New crystalline forms
US8084258B2 (en) * 1999-07-12 2011-12-27 University Of Basel Manipulation of tissue of organ type using the notch pathway
SE0001803D0 (sv) 2000-05-16 2000-05-16 Astrazeneca Ab New compounds i
US6433186B1 (en) 2000-08-16 2002-08-13 Astrazeneca Ab Amidino derivatives and their use as thormbin inhibitors
SE0102921D0 (sv) 2001-08-30 2001-08-30 Astrazeneca Ab Pharmaceutically useful compounds
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US7129233B2 (en) 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
US6287599B1 (en) 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US6811794B2 (en) 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
SE0201658D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Immediate release pharmaceutical formulation
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
US7781424B2 (en) 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
SE0303220D0 (sv) 2003-11-28 2003-11-28 Astrazeneca Ab New process
GB0503672D0 (en) 2005-02-23 2005-03-30 Astrazeneca Ab New process
GB0510546D0 (en) 2005-05-24 2005-06-29 Astrazeneca Ab New process
TW200827336A (en) 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms

Also Published As

Publication number Publication date
RU2323006C2 (ru) 2008-04-27
BR0210489A (pt) 2004-06-22
ZA200309316B (en) 2005-02-28
JP2005501024A (ja) 2005-01-13
SK286238B6 (sk) 2008-06-06
CZ20033491A3 (en) 2004-03-17
AU2002345463B2 (en) 2007-08-30
CO5550466A2 (es) 2005-08-31
IS7081A (is) 2003-12-16
SK15912003A3 (sk) 2004-05-04
ES2254699T3 (es) 2006-06-16
AR034517A1 (es) 2004-02-25
EP1401502B1 (de) 2005-12-28
US7700582B2 (en) 2010-04-20
KR20040011542A (ko) 2004-02-05
PL366432A1 (en) 2005-01-24
MY130332A (en) 2007-06-29
EE200400028A (et) 2004-04-15
IL159217A (en) 2009-02-11
DK1401502T3 (da) 2006-04-10
HUP0400850A3 (en) 2010-10-28
IS2347B (is) 2008-03-15
MXPA03011546A (es) 2004-03-19
CN1518462A (zh) 2004-08-04
NO20035627D0 (no) 2003-12-15
NZ530086A (en) 2005-09-30
RU2003136155A (ru) 2005-05-20
US20040242536A1 (en) 2004-12-02
UA77959C2 (en) 2007-02-15
WO2003000293A1 (en) 2003-01-03
HUP0400850A2 (hu) 2004-08-30
SI1401502T1 (sl) 2006-06-30
BG108516A (en) 2004-12-30
DE60208369D1 (de) 2006-02-02
DE60208369T2 (de) 2006-08-24
IL159217A0 (en) 2004-06-01
CZ299859B6 (cs) 2008-12-17
CA2450449A1 (en) 2003-01-03
EP1401502A1 (de) 2004-03-31

Similar Documents

Publication Publication Date Title
ATE314093T1 (de) Pharmazeutische formulierung enthaltend iota- carrageenan und mindestens ein gel-bildende neutrale polymer
DE69916288D1 (de) Lipasehemmer und chitosan enthaltende pharmazeutische zusammensetzungen
DE60318044D1 (de) Dialysesystem mit anzeige, web browser und web server
EE200300311A (et) Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim
ATE307571T1 (de) Pharmazeutische formulierung enthaltend bicalutamid
NO20033384L (no) Farmasoytisk formulering
DE60236183D1 (de) Anzeigegerät und dessen kontrollsystem
DE69838357D1 (de) Breitbandige reflektive Anzeigevorrichtung und ihre Herstellungsverfahren
ATE334656T1 (de) Flüssige pharmazeutische zusammensetzung
IS5662A (is) Þíenýlasólýlalkoxýetanamín, framleiðsla þeirra ognotkun sem lyf
DE59905572D1 (de) Substituierte 4-amino-2-aryl-pyrimidine, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate
EE200200607A (et) 2-atsüülindoolderivaadid ja nende kasutamine kasvajavastaste ravimitena
ATE383868T1 (de) Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka
IS7266A (is) Lyfjaform sem innihalda sýru-óþolin virk efni og aðferðir til tilreiðslu þeirra
DE60224785D1 (de) Drehwinkeldetektor und einrichtung mit dem detektor
DE60213003D1 (de) Tintenstrahlaufzeichnungsflüssigkeit und ihre herstellung
DE69802905D1 (de) Spandex mit niedriger klebrigkeit und herstellungsverfahren
FI20011370A (fi) Biotunnistusmenetelmä ja sitä hyödyntävä laite
DE60215756D1 (de) Verbinder und elektronisches Gerät mit dem Verbinder
ATE494278T1 (de) Anthranilsäureamide und ihre pharmazeutische verwendung
ID29871A (id) Turunan-turunan morfolin baru, metode pembuatannya dan komposisi-komposisi farmasi yang mengandungnya
PT1373249E (pt) Derivados de imidazolidina, sua preparacao e sua utilizacao como agente anti-inflamatorio
NO20004816D0 (no) Ny farmasøytisk formulering
NO20034787L (no) Anvendelse av pyridoindolonderivater var fremstilling av anticancer-medisiner
EE200300563A (et) Bensüülaminopürimidiiniühendid, nende kasutamine ja ravim

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1401502

Country of ref document: EP

REN Ceased due to non-payment of the annual fee